Were Hannah Valantine’s BridgeBio Pharma (BBIO) share sales under a Rule 10b5-1 plan?

Yes. The Form 4 states the transactions were effected under a Rule 10b5-1 sales plan adopted on November 14, 2025. Such pre-arranged trading plans allow insiders to schedule trades in advance, helping manage trading while limiting concerns about material nonpublic information.

BridgeBio director trades 25,484 BBIO shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma director Hannah Valantine exercised stock options for 25,484 shares on February 27, 2026, converting a “Stock Option (Right to Buy)” into common stock at an exercise price of $0.00 per share, with the resulting common shares reported at $48.45 per share.

On the same date, she sold 14,584 common shares at a weighted average price of $67.0793 and 10,900 shares at $67.8437 in open-market transactions executed under a Rule 10b5‑1 sales plan adopted on November 14, 2025. After these trades, she held 7,465 common shares directly and 398 shares indirectly through her spouse.

Insider Trade Summary

Exercise and Sale: 25,484 shares ($483K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Valantine Hannah

Role Director

Sold 25,484 shs ($1.72M)

Approx. gross sale proceeds $1.72M

Approx. exercise cost $1.23M

Approx. pre-tax spread $483K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	25,484	$0.00	$0.00
Exercise	Common Stock	25,484	$48.45	$1.23M
Sale	Common Stock	14,584	$67.0793	$978K
Sale	Common Stock	10,900	$67.8437	$739K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 7,465 shares (Direct); Common Stock — 398 shares (Indirect, By Spouse)

Footnotes (4)

F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.
F2. Represents the weighted average sale price of the shares sold from $66.42 to $67.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3. Represents the weighted average sale price of the shares sold from $67.42 to $68.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F4. The stock option vests and becomes exercisable in three annual installments after October 25, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BridgeBio Pharma (BBIO) director Hannah Valantine report in this Form 4?

Director Hannah Valantine reported exercising options for 25,484 BridgeBio Pharma shares and selling 25,484 common shares in open-market transactions. The filing also shows her remaining direct and indirect share ownership after these trades on February 27, 2026.

How many BridgeBio Pharma (BBIO) shares did Hannah Valantine sell and at what prices?

Hannah Valantine sold 14,584 BridgeBio Pharma common shares at a weighted average price of $67.0793 and 10,900 shares at $67.8437. Both transactions were open-market or private sales executed on February 27, 2026, as disclosed in the Form 4.

How many BridgeBio Pharma (BBIO) shares does Hannah Valantine own after these transactions?

After the transactions, Hannah Valantine directly owned 7,465 BridgeBio Pharma common shares. The Form 4 also reports 398 shares held indirectly, attributed to her spouse, reflecting both her direct and indirect holdings as of February 27, 2026.

What option exercise did Hannah Valantine report for BridgeBio Pharma (BBIO)?

She reported exercising a “Stock Option (Right to Buy)” for 25,484 shares at an exercise price of $0.00 per share. The converted common stock was reported at $48.45 per share, and the option relates to a grant vesting over three years after October 25, 2021.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/03/2026 - 04:17 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valantine Hannah

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/27/2026		M		25,484	A	$48.45	32,949	D
Common Stock	02/27/2026		S⁽¹⁾		14,584	D	$67.0793⁽²⁾	18,365	D
Common Stock	02/27/2026		S⁽¹⁾		10,900	D	$67.8437⁽³⁾	7,465	D
Common Stock								398	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$48.45	02/27/2026		M			25,484	⁽⁴⁾	10/24/2031	Common Stock	25,484	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.

2. Represents the weighted average sale price of the shares sold from $66.42 to $67.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. Represents the weighted average sale price of the shares sold from $67.42 to $68.31 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

4. The stock option vests and becomes exercisable in three annual installments after October 25, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR